Cambridge scientists have developed a urine test for early detection of lung cancer. The test, the first of its kind, detects ‘zombie’ cells that could indicate the first signs of the disease.
Researchers hope that early detection, through the simple urine test, could enable earlier treatment interventions, significantly improving patient outcomes and prognosis. Professor Ljiljana Fruk and Dr Daniel Munoz Espin and their teams at the University of Cambridge are leading on the research, funded by Cancer Research UK. The work, at Cambridge’s Department of Chemical Engineering and Biotechnology, and the Early Cancer Institute, will provide a cheap, affordable sensor that uses urine samples to help doctors detect lung cancer before the disease develops.
Lung cancer has a poor prognosis for many patients because often there are no noticeable symptoms until it has spread through the lungs or into other parts of the body. The new urine test will allow doctors to spot the disease before it develops.
To create the test, scientists looked at proteins excreted by senescent cells: “zombie” cells which are alive but unable to grow and divide. It’s these cells that cause tissue damage by reprogramming their immediate environment to help promote the emergence of cancer cells. Now, researchers have developed an injectable sensor that interacts with zombie cell proteins and releases easily detectable compound into urine, signalling their presence.
“Early detection of cancer requires cost-effective tools and strategies that enable detection to happen quickly and accurately,” said Fruk. “We designed a test based on peptide-cleaving proteins, which are found at higher levels in the presence of zombie cells, and in turn appear in the early stages of cancer.
“Ultimately, we want to develop a urine test that could help doctors identify signs of the early stages of cancer – potentially months or even years before noticeable symptoms appear.”
As well as targeting lung cancer, Fruk hopes her research, along with joint efforts across other university departments, will result in the development of probes capable of detecting other cancers.
“We have almost completed a functional urine test to detect ‘zombie' cells in lung cancer, which will spot cancer earlier and avoid the need for invasive procedures, but this test does have potential for other cancers,” she said. “Developing more efficient cancer treatments requires earlier detection and better therapies, but also work with other disciplines for a more holistic view of the disease, which is an essential part of my research.”
From uncovering the causes of lung cancer to pioneering drugs to treat it, Cancer Research UK has helped power progress for people affected by lung cancer. Over the last 10 years, the charity has invested over £231 million in lung cancer research.
“Cancer Research UK has played a key role in advancing lung cancer research and improving survival,” said Dr Iain Foulkes, Cancer Research UK’s executive director of research and innovation. “This project being led by Professor Fruk is another example of our commitment to driving progress so that more people can live longer, better lives, free from the fear of cancer.”
